Hemogenyx Pharmaceuticals (HEMO) Competitors GBX 174.20 +4.45 (+2.62%) As of 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock HEMO vs. AOR, FAB, POLB, RLM, APTA, NSCI, OPTI, IXI, SNG, and OBDShould you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include AorTech International (AOR), Fusion Antibodies (FAB), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), Aptamer Group (APTA), NetScientific (NSCI), OptiBiotix Health (OPTI), IXICO (IXI), Synairgen (SNG), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry. Hemogenyx Pharmaceuticals vs. Its Competitors AorTech International Fusion Antibodies Poolbeg Pharma Realm Therapeutics Aptamer Group NetScientific OptiBiotix Health IXICO Synairgen Oxford BioDynamics AorTech International (LON:AOR) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Which has stronger valuation & earnings, AOR or HEMO? AorTech International has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAorTech International£539K0.00N/A-£3.70N/AHemogenyx PharmaceuticalsN/AN/A-£6.89K-£0.20-891.13 Does the media prefer AOR or HEMO? In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.84 beat AorTech International's score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment AorTech International Neutral Hemogenyx Pharmaceuticals Positive Is AOR or HEMO more profitable? AorTech International's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AorTech InternationalN/A N/A N/A Hemogenyx Pharmaceuticals N/A -80.66%-37.79% Do insiders and institutionals hold more shares of AOR or HEMO? 0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAorTech International and Hemogenyx Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks. Get Hemogenyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEMO vs. The Competition Export to ExcelMetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.21M£137.08M£5.76B£3.22BDividend YieldN/A3.74%4.41%5.04%P/E Ratio-891.133.8731.10164.63Price / SalesN/A4,053.59470.24310,107.36Price / Cash2.0513.1937.7327.93Price / Book707.1046.309.535.90Net Income-£6.89K-£90.99M£3.26B£5.89B7 Day Performance15.84%0.61%2.11%48.33%1 Month Performance-1.16%3.58%5.12%49.98%1 Year Performance13,300.00%197.78%31.25%127.65% Hemogenyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEMOHemogenyx PharmaceuticalsN/AGBX 174.20+2.6%N/A+12,750.1%£6.21MN/A-891.1314High Trading VolumeAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383FABFusion AntibodiesN/AGBX 17.70+4.1%N/A+338.6%£16.65M£2.09M-3.9848Positive NewsPOLBPoolbeg PharmaN/AGBX 2.98+1.1%N/A-75.9%£15.33MN/A0.0012Gap DownRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501.92K-0.66N/AAPTAAptamer GroupN/AGBX 0.67+3.7%N/A+162.5%£13.40M£4.12M-0.9537News CoverageGap DownHigh Trading VolumeNSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 11.98+6.4%N/A-50.9%£11.73M£590.01K-3.791Gap UpIXIIXICON/AGBX 12.50+2.0%N/A+22.3%£11.58M£11.50M-3.2489SNGSynairgenN/AN/AN/AN/A£9.04MN/A-0.5634Gap DownOBDOxford BioDynamicsN/AGBX 0.44+4.5%N/A-92.9%£8.37M£5.75M-0.0845 Related Companies and Tools Related Companies AorTech International Alternatives Fusion Antibodies Alternatives Poolbeg Pharma Alternatives Realm Therapeutics Alternatives Aptamer Group Alternatives NetScientific Alternatives OptiBiotix Health Alternatives IXICO Alternatives Synairgen Alternatives Oxford BioDynamics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:HEMO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access